Why Biogen Needs Yet Another Multiple Sclerosis Drug
Late last week the Food and Drug Administration announced its approval of yet another drug to treat multiple sclerosis, this one touted as the only once-a-month, self-administered injection to treat relapsing forms of the disease.
But in light of the fact that Cambridge-based Biogen (Nasdaq: BIIB) already sells five other drugs for the disease (four of them in the U.S.), and this one is expected to only make a fraction of the revenues of company’s biggest-selling one, it’s fair to ask: Why bother?
But in light of the fact that Cambridge-based Biogen (Nasdaq: BIIB) already sells five other drugs for the disease (four of them in the U.S.), and this one is expected to only make a fraction of the revenues of company’s biggest-selling one, it’s fair to ask: Why bother?